OP022 Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: data from the CELEST study
Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Ana P. Lacerda(AbbVie (United States)), Laurent Peyrin‐Biroulet(Délégation Centre-Est), S Goteti(AbbVie (United States)), Wen Zhou(Academy of Medical Sciences), Alessandro Armuzzi, Gabriela Alperovich(AbbVie (Spain)), Peter Higgins(Michigan Medicine), Brigid S. Boland, Jonathan P. Terdiman(UCSF Helen Diller Family Comprehensive Cancer Center), Fabio Cataldi(Pfizer (United States))
Cited by 14
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k